Graça Diogo, Louro Henriqueta, Santos Joana, Dias Kamila, Almeida Antonio J, Gonçalves Lídia, Silva Maria João, Bettencourt Ana
Research Institute for Medicines (iMed.ULisboa), Faculdade de Farmácia, Universidade de Lisboa, Avenida Prof. Gama Pinto, 1649-003, Lisboa, Portugal; REQUIMTE, Departamento de Química, Faculdade de Ciências e Tecnologia, Universidade Nova de Lisboa, 2829-516 Caparica, Portugal; Instituto Nacional de Saúde Doutor Ricardo Jorge, I.P. (INSA), Av. Padre Cruz, 1649-16 Lisboa, Portugal.
Instituto Nacional de Saúde Doutor Ricardo Jorge, I.P. (INSA), Av. Padre Cruz, 1649-16 Lisboa, Portugal; Centre for Toxicogenomics and Human Health (ToxOmics), Nova Medical School/Faculdade de Ciências Médicas, Universidade Nova de Lisboa, Rua Câmara Pestana, 6, 1150-082 Lisboa, Portugal.
Toxicol Lett. 2017 Jul 5;276:129-137. doi: 10.1016/j.toxlet.2017.05.017. Epub 2017 May 17.
Translation of innovative drug delivery nanosystems into the market involves an early toxicity screening in the development phase. Previously, we showed that inclusion of the polymer Eudragit (EUD) into poly(methylmethacrylate) (PMMA) nanoparticles (NP) resulted in a novel nanocarrier (PMMA-EUD) with an improved biomedical performance. The safety of this novel nanoparticulate system (PMMA-EUD) was assessed in this work and compared to that of the original PMMA by using an integrated approach, comprising in vitro toxicity assessment and NPs physicochemical characterization in water and cell medium. For toxicity assessment several endpoints were analysed, including cell death, oxidative stress, and genotoxicity using L929 fibroblasts. PMMA-EUD proved to be more hydrophobic than the original PMMA. Also, charge of both NPs was strongly affected by cell medium. On the other hand, the novel nanosystem was easily uptaken by L929 cells and did not display relevant in vitro cytotoxic or genotoxic effects. On the contrary, PMMA were less internalized in cells and proved to be genotoxic, as measured by the micronucleus assay. To conclude, our results provide initial evidence about the safety of the novel and promising PMMA-EUD nanoparticulate system, enabling its further development towards applications for drug delivery.
将创新型药物递送纳米系统推向市场需要在研发阶段进行早期毒性筛选。此前,我们发现将聚合物Eudragit(EUD)加入聚甲基丙烯酸甲酯(PMMA)纳米颗粒(NP)中可形成一种具有改善生物医学性能的新型纳米载体(PMMA-EUD)。本研究通过综合方法评估了这种新型纳米颗粒系统(PMMA-EUD)的安全性,并与原始PMMA的安全性进行了比较,该方法包括体外毒性评估以及纳米颗粒在水和细胞培养基中的物理化学表征。为了进行毒性评估,分析了几个终点指标,包括使用L929成纤维细胞分析细胞死亡、氧化应激和遗传毒性。结果表明,PMMA-EUD比原始PMMA更疏水。此外,两种纳米颗粒的电荷都受到细胞培养基的强烈影响。另一方面,新型纳米系统很容易被L929细胞摄取,并且在体外未显示出相关的细胞毒性或遗传毒性作用。相反,通过微核试验测量,PMMA在细胞中的内化较少,并且被证明具有遗传毒性。总之,我们的结果为新型且有前景的PMMA-EUD纳米颗粒系统的安全性提供了初步证据,使其能够进一步朝着药物递送应用方向发展。